Enterprise Therapeutics Raises £29M To Advance Respiratory Assets

12 Apr 2018

• By Mike Ward

UK biopharma Enterprise Therapeutics raises £29M in a series B round co-led by Versant Ventures and Novartis Venture Fund to advance pipeline of novel respiratory disease treatments into clinical development.

Enterprise Therapeutics Raises £29M To Advance Respiratory Assets

More from Business

More from Scrip